Abstract
In 37 adults with chronic myeloid leukemia undergoing allogeneic stem cell transplantation imatinib prior to transplant had no discernible negative impact on 100-day mortality (13%) and severe acute (22%) or extensive chronic graft-versus- host disease (31%). After a median of 203 days (range: 18-1419) overall and progression-free survival rates are 62% and 54%, respectively.
Vol. 91 No. 8 (2006): August, 2006 : Letters to the Editor
Published By
Ferrata Storti Foundation, Pavia, Italy
Statistics from Altmetric.com
